8 results

The health service could save up to €1 billion in its medicines budget over the next five years, according to the group representing the sector. Photograph: Getty

(...). Medicines for Ireland says that the use of generics and biosimilars has saved the State €1.6 billion since(...)

Take-up of biosimilars in the Irish health system has been held back by the lack of Government encouragement and inertia among medical practitioners. Photograph: Benis Arapovic/Getty

Efforts to pull together a national policy on biosimilars remain stymied somewhere in the(...)

Shot of drug bottles on a conveyor. iStock

(...) 2017 to target 50 per cent of prescriptions in hospitals of biosimilars – “copycat”drugs with no(...)

IPHA president GSK’s Aidan Lynch (centre); IPHA vice-president Paul Reid (Pfizer); and Bayer’s Itziar Canamasas with the Manifesto for Better Health ahead of the IPHA annual conference on November 8th. Photograph: Justin Mac Innes

(...) policy on biosimilars remains just that – a promise. The consultation process is complete, but there is(...)

 Industry sources say the State  lost between €4 million and €5 million by the delay in reducing the price of Pfizer’s  blockbuster arthritis drug  Enbrel. Photograph: Paul Faith/AFP/Getty Images

(...) medicine is a cheaper identical “copy” of a branded traditional small-molecule drug, biosimilars are “me(...)

The HEA has written to Minister for Health Simon Harris expressing its concern over what it calls the “biosimilar blocker”. Photograph: Dave Meehan

(...) beginning to see competition from “biosimilars”. Large molecule protein drugs, biologics cannot be precisely(...)

 Minister for Health Simon Harris:  in the letter sent to him the Healthcare Enterprise Alliance says the pricing agreement includes “artificial pricing thresholds”. Photograph: Dave Meehan

(...) four years. However, a lobby group representing the makers of generics and “biosimilars” – copies of(...)

The headquarters of Merck KGaA in Darmstadt, Germany. Photographer: Hannelore Foerster/Bloomberg

(...) of competition.Karl-Ludwig Kley, chief executive of the German group, said he expected “biosimilars(...)